NCT06025344

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)

A Single Dose Oral Bioavailability Study of PanCytoVir™ Oral Suspension (100 mg/ml) 1000 mg Versus Probenecid 500 mg Tablets, 1000 mg (2 X 500 mg) in Healthy, Adult, Human Subjects Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: TrippBio, Inc. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral relative bioavailability study of a novel PanCytoVir™ oral suspension (100 mg/mL) versus probenecid 500 mg tablets in normal healthy, adult, human subjects under fasting conditions.

Conditions

• Relative Bioavailability

Interventions

Type	Name	Description
DRUG	PanCytoVir™ 100 mg/mL oral suspension	Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
DRUG	Probenecid 500 mg	Single oral dose of 1000 mg under fasted conditions

Timeline

• Start date: 2024-09-01
• Primary completion: 2024-09-30
• Completion: 2024-10-15
• First posted: 2023-09-06
• Last updated: 2024-11-21

Locations

1 site across 1 country: India